Research programme: cancer therapeutics - PHusis Therapeutics

Drug Profile

Research programme: cancer therapeutics - PHusis Therapeutics

Alternative Names: PHT-427; PHT-7.3

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator PHusis Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 3-phosphoinositide dependent-protein-kinase-inhibitors; KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma; Solid tumours

Most Recent Events

  • 02 Jun 2017 PHT 427 is still in pre-clinical trials for Solid tumours in USA (PHusis Therapeutics website, June 2017)
  • 02 Jun 2017 PHusis plans phase I trials for PHT 427 and PHT 7.3 (PHusis Therapeutics website, June 2017)
  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top